Evaluation of a cohort of long-term surviving patients with glioblastoma
Authors:
R. Bartoš 1; D. Bondar 1; A. Malucelli 1; A. Hejčl 1; P. Vachata 1; A. Sejkorová 1; I. Humhej 1; M. Sameš 1; D. Šmejkalová 2; V. Kříha 3; F. Třebický 4; G. Šimonová 5; M. Trnková 6; D. Ospalík 7; T. Kazda 8
Authors‘ workplace:
Neurochirurgická klinika Univerzity J. E. Purkyně, Masarykova nemocnice, KZ a. s., Ústí nad Labem
1; Onkologická klinika Univerzity J. E. Purkyně, Masarykova nemocnice, KZ a. s., Ústí nad Labem
2; Ústav radiační onkologie FN Bulovka, Praha
3; Ústav radiační terapie ÚVN – VFN, Praha
4; Oddělení stereotaktické a radiační neurochirurgie, Nemocnice Na Homolce, Praha
5; Aeskulab Patologie, k. s., Praha
6; Neurologické oddělení, Masarykova nemocnice, KZ a. s., Ústí nad Labem
7; Klinika radiační onkologie a Výzkumné centrum aplikované molekulární onkologie (RECAMO), Masarykův onkologický ústav, Brno
8
Published in:
Cesk Slov Neurol N 2025; 88(5): 297-303
Category:
Original Paper
doi:
https://doi.org/10.48095/cccsnn2025297
Overview
Aim: The aim of this study is to analyze a cohort of patients with glioblastoma multiforme treated at the neurosurgery department in Ústí nad Labem, whose overall survival time exceeded 3 years. Patients and methods: In a prospectively conducted group of 22 patients, we confirmed glioblastoma IDH wildtype in 21 patients, including the Ki-67 proliferation index, including examination of samples after repeated resections. We describe the therapeutic procedure of patients in the cohort: Stupp regimen including subsequent administration of chemotherapy beyond 6 cycles, number of reoperations, and use of stereotactic radiosurgery using a gamma knife. In addition to comparison with other published cohorts, we evaluate the preoperative characteristics of tumors on MRI, namely the presence of midline shift greater than 10 mm, involvement of the right or left hemisphere, and involvement of the cortex or periventricular region. Results: The median overall survival, excluding survival estimates for 11 living patients according to Kaplan-Meier, is 53 months (4.4 years) ranging from 38 months to 228 months (19 years). In the analysis of the entire patient population (including censoring of surviving patients), we observed a median overall survival of 142 months (11.8 years) at a median follow-up of 74 months, with a 95% confidence interval for the median survival time ranging from 46 to 142 (not reached) months. Survival time > 4 years was observed in 15 patients (71%), > 5 years in 10 patients (48%), and 10 years or more in 6 patients (29%). Conclusion: The effort to achieve the most radical resection and completion of radiochemotherapy according to the Stupp protocol were the common denominators in our cohort of 21 patients with glioblastoma multiforme IDH wildtype with overall survival > 3 years. We cannot confirm the adverse effect of the primary characteristics of MRI of the tumor – the initial midline overpressure and the involvement of the periventricular region.
Sources
1. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352 (10): 987–996. doi: 10.1056/NEJMoa043330.
2. Bartoš R, Ospalík D, Malucelli A et al. Retrospektivní autoevaluace výsledků operací intrinsických mozkových nádorů – konsekutivní kohorta 270 operací v rámci jednoho neurochirurgického centra NOS ČOS (Neuroonkologické sekce České onkologické společnosti) z let 2015–2017. Cesk Slov Neurol N 2019; 82/115 (4): 401–409. doi: 10.14735/amcsnn2019401.
3. Halaj M, Kalita O, Šlachta M et al. Vztah mezi objemem postresekčního rezidua a celkovým přežíváním pacientů s glioblastomem – studie v rámci jednoho neuroonkologického centra. Cesk Slov Neurol N 2024; 87 (1): 53–60. doi: 10.48095/cccsnn202453.
4. Louis DN, Perry A, Wesseling P et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021; 23 (8): 1231–1251. doi: 10.1093/neuonc/noab106.
5. Hendrych M, Barák M, Valeková H et al. Přehled difuzních gliomů dle WHO klasifikace 2021 – 1. část: difuzní gliomy dospělého typu. Cesk Slov Neurol N 2023; 86/119 (6): 359–368. doi: 10.48095/cccsnn2023359.
6. Krex D, Klink B, Hartmann C et al. Long-term survival with glioblastoma multiforme. Brain 2007; 130 (Pt 10): 2596–2606. doi: 10.1093/brain/awm204.
7. Mirestean CC, Iancu RI, Iancu DPT. Re-irradiation in high-grade gliomas – a topic still under debate. Cesk Slov Neurol N 2025; 88 (2): 89–94. doi: 10.48095/cccsnn202589.
8. Bartoš R, Šoula O, Šimonová G. Léčba recidivy či rezidua multiformního glioblastomu pomocí stereotaktické radiochirurgie (gama nůž) – společně hodnocený soubor dvou neurochirurgických pracovišť. Cesk Slov Neurol N 2018; 81/114 (5): 556–562. doi: 10.14735/amcsnn2018556.
9. Huang B, Yu Z, Liang R. Effect of long-term adjuvant temozolomide chemotherapy on primary glioblastoma patient survival. BMC Neurol 2021; 21 (1): 424. doi: 10.1186/s12883-021-02461-9.
10. Hertler C, Felsberg J, Gramatzki D et al. Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders‘ Collaborative Consortium (EORTC 1419). Eur J Cancer 2023; 189 : 112913. doi: 10.1016/j.ejca.2023.05.002.
11. Marton E, Giordan E, Siddi F et al. Over ten years overall survival in glioblastoma: A different disease? J Neurol Sci 2020; 408 : 116518. doi: 10.1016/j.jns.2019.116518.
12. Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci 2018; 54 : 7–13. doi: 10.1016/j.jocn.2018.05.002.
13. Hendrych M, Barák M, Valeková H et al. Přehled difuzních gliomů dle WHO klasifikace 2021 – 2. část: difuzní gliomy dětského typu. Cesk Slov Neurol N 2024; 87/120 (1): 9–17. doi: 10.48095/cccsnn202409.
14. Madhugiri VS, Moiyadi AV, Shetty P et al. Analysis of factors associated with long-term survival in patients with glioblastoma. World Neurosurg 2021; 149 : 758–765. doi: 10.1016/j.wneu.2021.01.013.
15. Zreik J, Moinuddin FM, Yolcu YU et al. Improved 3-year survival rates for glioblastoma multiforme are associated with trends in treatment: analysis of the National Cancer Database from 2004 to 2013. J Neurooncol 2020; 148 (1): 69–79. doi: 10.1007/s11060-020-03467-2.
16. Wach J, Hamed M, Schuss P et al. Impact of initial midline shift in glioblastoma on survival. Neurosurg Rev 2021; 44 (3): 1401–1409. doi: 10.1007/s10143-020-01328-w.
17. Prasanna P, Mitra J, Beig N et al. Mass Effect Deformation Heterogeneity (MEDH) on Gadolinium-contrast T1-weighted MRI is associated with decreased survival in patients with right cerebral hemisphere glioblastoma: a feasibility study. Sci Rep 2019; 9 (1): 1145. doi: 10.1038/s41598-018-37615-2.
18. Adeberg S, Bostel T, König L et al. A comparison of long-term survivors and short-term survivors with glioblastoma, subventricular zone involvement: a predictive factor for survival? Radiat Oncol 2014; 9 : 95. doi: 10.1186/1748-717X-9-95.
19. Clavreul A, Lemée JM, Soulard G et al. A simple preoperative blood count to stratify prognosis in isocitrate dehydrogenase-wildtype glioblastoma patients treated with radiotherapy plus concomitant and adjuvant temozolomide. Cancers (Basel) 2021; 13 (22): 5778. doi: 10.3390/cancers13225778.
Labels
Paediatric neurology Neurosurgery NeurologyArticle was published in
Czech and Slovak Neurology and Neurosurgery
2025 Issue 5
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Memantine Eases Daily Life for Patients and Caregivers
- Hope Awakens with Early Diagnosis of Parkinson's Disease Based on Skin Odor
Most read in this issue
- Anatomy of ulnar nerve entrapment
- Effects of whole-course case management in combination with mind mapping on neurological functions and prognosis of patients receiving hematoma evacuation for hypertensive cerebral hemorrhage
- Embolization of the middle meningeal artery as a treatment of chronic subdural hematoma – a single-center experience
- Léčba epilepsie – vytyčení cíle a hledání lepší cesty k němu